We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+17.58%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$2.97B
AUM Growth
+$703M
Cap. Flow
+$803M
Cap. Flow %
27.04%
Top 10 Hldgs %
34.36%
Holding
350
New
119
Increased
64
Reduced
60
Closed
59

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$25.3M
2
LLY icon
Eli Lilly
LLY
+$24.5M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$18.4M
4
XFOR icon
X4 Pharmaceuticals
XFOR
+$15.7M
5
MGNX icon
MacroGenics
MGNX
+$12.2M

Top Sells

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$21.4M
2
KALV
KalVista Pharmaceuticals
KALV
+$20.2M
3
BMY icon
Bristol-Myers Squibb
BMY
+$17.9M
4
CLDX icon
Celldex Therapeutics
CLDX
+$17.7M
5
PRTA icon
Prothena Corp
PRTA
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 22.28%
2 Consumer Staples 0.05%
3 Financials 0.03%
4 Industrials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QNCX icon
326
CALL
Quince Therapeutics
QNCX
$22.9M
– –
-140
Closed -$776K
QNCX icon
327
Quince Therapeutics
QNCX
$22.9M
– –
-65
Closed -$361K
QNCX icon
328
PUT
Quince Therapeutics
QNCX
$22.9M
– –
-850
Closed -$4.72M
RAPT
329
PUT
DELISTED
RAPT Therapeutics
RAPT
– –
-1,950
Closed -$309K
RIGL icon
330
Rigel Pharmaceuticals
RIGL
$681M
– –
-34,553
Closed -$1.21M
SNDX icon
331
CALL
Syndax Pharmaceuticals
SNDX
$1.69B
– –
-100,000
Closed -$2.22M
ZYME icon
332
CALL
Zymeworks
ZYME
$1.61B
– –
-375,200
Closed -$17.7M
ZYME icon
333
Zymeworks
ZYME
$1.61B
– –
-1,556
Closed -$73K
ZYME icon
334
PUT
Zymeworks
ZYME
$1.61B
– –
-580,200
Closed -$27.4M
QTTB icon
335
PUT
Q32 Bio
QTTB
$466M
– –
-5,556
Closed -$1.13M
DCPH
336
CALL
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-140,000
Closed -$7.99M
KRTX
337
CALL
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-120,000
Closed -$12.2M
MRTX
338
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-3,557
Closed -$704K
OTIC
339
DELISTED
Otonomy, Inc.
OTIC
– –
-259,337
Closed -$1.68M
CLVS
340
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-650,000
Closed -$3.12M
CCXI
341
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-37
Closed -$2.23K
GBT
342
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-200,000
Closed -$8.66M
GBT
343
PUT
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-2,100
Closed -$91K
XLRN
344
PUT
DELISTED
Acceleron Pharma
XLRN
– –
-100,000
Closed -$12.8M
GWPH
345
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-8
Closed -$1.5K
FSDC
346
DELISTED
FS Development Corp. Class A Common Stock
FSDC
– –
-350,000
Closed -$3.85M
BMY.RT
347
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
– –
-644,021
Closed -$444K
HZNP
348
PUT
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-265,000
Closed -$19.4M
BHVN
349
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-119,100
Closed -$10.2M
BHVN
350
PUT
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-104,100
Closed -$8.92M
10 11 12 13
14

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Ikarian Capital held 350 positions worth $2.97B, up 31% from $2.27B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Ikarian Capital deployed $803M of net new capital in Q1 2021, opening 119 new positions and adding to 64 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 1,336,412 shares worth $4.57M.

By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 24% a quarter earlier, followed by Consumer Staples and Financials.

On the sell side, the largest reduction was Morphic Holding, Inc. Common Stock, an estimated $21.4M trimmed.

  • Ikarian Capital's largest Q1 2021 buy was Odonate Therapeutics, Inc. Common Stock: 1,336,412 shares worth $4.57M.
  • Ikarian Capital added most to X4 Pharmaceuticals in Q1 2021, an estimated $15.7M increase.
  • Ikarian Capital's biggest Q1 2021 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $21.4M.
  • Ikarian Capital fully exited Bristol-Myers Squibb in Q1 2021, selling an estimated $17.9M.
  • Ikarian Capital's ten largest holdings make up 34% of its $2.97B portfolio in Q1 2021.
  • Ikarian Capital opened 119 new positions and closed 59 in Q1 2021.
  • Ikarian Capital's portfolio value rose 31% quarter-over-quarter to $2.97B.

Based on Ikarian Capital's 13F filing for Q1 2021, filed 17 May 2021.